Frontier Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Frontier Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-19,782	Closed	-$1.9M	–	290
2020 Q3	$1.9M	Sell	19,782 -20,580	-51%	-$2.38M	0.02%	282
2020 Q2	$4.92M	Buy	+40,362	New	+$4.46M	0.04%	259
2019 Q2	–	Sell	-188,328	Closed	-$16.6M	–	299
2019 Q1	$16.6M	Sell	188,328 -175,144	-48%	-$14.6M	0.12%	205
2018 Q4	$26M	Sell	363,472 -42,242	-10%	-$4.05M	0.21%	151
2018 Q3	$49.9M	Sell	405,714 -241,209	-37%	-$27.4M	0.32%	125
2018 Q2	$63.6M	Sell	646,923 -179,349	-22%	-$16.1M	0.45%	83
2018 Q1	$68.5M	Buy	826,272 +706,047	+587%	+$59.6M	0.5%	68
2017 Q4	$9.33M	Buy	+120,225	New	+$8.2M	0.07%	233

Other funds holding NBIX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Frontier Capital Management's NBIX Position: Q4 2020 in Review

Frontier Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 19,782 shares — an estimated $1.9M sold.

Frontier Capital Management first reported a position in NBIX in Q4 2017 and held it in 8 quarters. The position peaked at $68.5M in Q1 2018. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

Frontier Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
Frontier Capital Management sold 19,782 Neurocrine Biosciences shares in Q4 2020, an estimated $1.9M.
Frontier Capital Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 8 quarters.
Frontier Capital Management's Neurocrine Biosciences position peaked at $68.5M in Q1 2018.
406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Frontier Capital Management's 13F filing for Q4 2020, filed 19 Jan 2021.